Inhibitors of spns2 and uses thereof
AssigneeNew York University
InventorsJohn Kenneth DICKSON, JR., Susan SCHWAB, Xinyan HUANG
Life of this patent
Estimating the term…
Abstract
Compounds are disclosed that have a formula (I) and wherein R1, R2, R3, R4, X, and Y are as described herein. The compounds may be prepared as compositions, e.g., pharmaceutical compositions, or as dosage forms, e.g., pharmaceutical dosage forms, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, autoimmune diseases, such as multiple sclerosis (MS) and inflammatory bowel disease (IBD), fibrosis, muscle wasting, metastases, acute lung injury, rheumatoid arthritis, colitis, Alzheimer's disease, and other diseases related to Sphingolipid Transporter 2 (SP-NS2) activity.
Claims32
A compound having a structure according to Formula (I):
- wherein:
- X is —C(H)═ or —N═;
- Y is —C(H)═ or —N═, wherein at least one of X and Y is not —C(H)═;
- R1 is a hydrogen, —Cl, —F, or a C1-C6 alkyl;
- R2 is a hydrogen, —Cl, —F, or a C1-C6 alkyl;
- R3 is —Cl, R5, —OR5, —NHR5, or —N(R5)2;
- R4 is —OR5, —NHR5, —N(R5)2,
- R5 is independently at each occurrence an optionally substituted C1-C12 alkyl, an optionally substituted C1-C12 alkenyl, an optionally substituted C1-C12 alkoxy, an optionally substituted ring selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclyl, a 4-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S, a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from N, O, and S, a fused bicyclic ring system having 1-4 heteroatoms independently selected from N, O, and S, or an optionally substituted combination of any two of a C1-C12 alkyl, a C1-C12 alkenyl and a ring;
- Z is —C(H)—, —CH2—, or —O—;
- R6 is independently at each occurrence an optionally substituted C1-C12 alkyl;
- an optionally substituted C1-C12 alkenyl;
- an optionally substituted phenyl, —N(R*)2, —OR*, —N(R*)C(O)R*, —NH—SO2—R*, —C(O)N(R*)2, or
- R* is independently at each occurrence hydrogen, an optionally substituted C1-C12 alkyl, an optionally substituted C1-C12 polyfluoroalkyl;
- an optionally substituted phenyl, an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclyl;
- a 4-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S,
- or a pharmaceutically acceptable salt thereof,
- with a proviso that wherein (i) R1 and R2 are both hydrogens, X and Y are both —N═, and R3 is a 6 membered saturated heterocyclyl having 2 nitrogen atoms, R4 is not
- (ii) R1 and R2 are both hydrogens, X and Y are both —N═, and R3 is phenyl substituted with —OCH3 or —F,
- R4 is not
- or
- (iii) R1 is a hydrogen, —Cl, —F, or a C1-C6 alkyl;
- R2 is a hydrogen, —Cl, —F, or a C1-C6 alkyl;
- X is —N═;
- Y is —C(H)═ or —N═;
- and R3 is —CH3 or a combination of C1-C4 alkylene and a fused bicyclic ring system consisting of two fused six-membered aromatic rings containing at least one nitrogen atom, R4 is not
-3. (canceled)
-6. (canceled)
-19. (canceled)
(canceled)
-24. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-40. (canceled)
-44. (canceled)
(canceled)
Dependencies are inferred from the claim text.